Researchers at the University of Bath, in collaboration with the Universities of Oxford and Bristol, have developed a peptide molecule that prevents alpha-synuclein—a protein linked to Parkinson’s disease and related dementias—from clumping into toxic aggregates that kill brain cells. The engineered peptide works by locking alpha-synuclein into its healthy helical shape, which is essential for its normal function in dopamine transport, thereby blocking its conversion into the harmful clumps that cause symptoms like tremors and muscle stiffness. Laboratory tests demonstrated that the peptide is stable, can penetrate brain-like cells, and successfully restored movement while reducing protein deposits in a worm model of Parkinson’s disease. This breakthrough, published in JACS Au, represents a significant advance in rational peptide design and offers a promising new approach to developing treatments for neurodegenerative diseases that currently have no cure. While further research is needed before clinical testing, the findings suggest potential for future therapies that could slow or halt disease progression in Parkinson’s and dementia with Lewy bodies.
Image credit: Julia Koblitz / Unsplash